MapLight’s schizophrenia drug dampens once-daily hopes despite Phase 2 win

Phase 2MixedNegative

AI Analysis

Summary

MapLight Therapeutics' once-daily schizophrenia drug regimen failed to meet the primary endpoint in a Phase 2 trial despite overall study success, causing the company's stock to plummet over 60%.

Clinical Trial Data

Phase

Phase 2

Primary Endpoint

Not Met

Outcome Details

Once-daily regimen missed primary endpoint despite overall study success

Importance:7/10

Sentiment:

-0.85

schizophreniaPhase 2clinical trialstock declinemissed endpoint

Related Companies

$MPLT

Read the original article

Published by Endpoints News on July 27, 2026 3:17 PM

Read Original